ICONOVO AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.8 SEK | -2.70% |
|
+2.37% | -6.49% |
| May. 15 | Iconovo AB Files Patent Application for Inhaled GLP-1 Products and Initiates Development of New Obesity Treatments | CI |
| May. 06 | Sweden's Iconovo to Receive Chinese Patent for ICOres Inhaler | MT |
| Sales 2024 * | 52.65M 4.97M | Sales 2025 * | 76.4M 7.21M | Capitalization | 172M 16.23M |
|---|---|---|---|---|---|
| Net income 2024 * | -21M -1.98M | Net income 2025 * | -25M -2.36M | EV / Sales 2024 * | 2.53 x |
| Net cash position 2024 * | 38.6M 3.64M | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.25 x |
| P/E ratio 2024 * |
-5.4
x | P/E ratio 2025 * |
-6.55
x | Employees | 29 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 62.44% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -2.70% | ||
| 1 week | +2.37% | ||
| Current month | +33.33% | ||
| 1 month | +39.18% | ||
| 3 months | +38.82% | ||
| 6 months | +22.73% | ||
| Current year | -6.49% |
1 week
10.15
12.25
1 month
7.7012.25
Current year
7.4612.55
1 year
7.4635.00
3 years
7.4699.80
5 years
7.4699.80
10 years
7.4699.80
| Managers | Title | Age | Since |
|---|---|---|---|
Johan Wäborg
CEO | Chief Executive Officer | 47 | 20-04-13 |
Orest Lastow
FOU | Founder | 60 | 12-12-31 |
Henrik Simonsen
DFI | Director of Finance/CFO | 61 | 23-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 63 | 12-12-31 | |
Gunnar Gårdemyr
CHM | Chairman | 65 | 21-04-30 |
Ann Gidner
BRD | Director/Board Member | 58 | 20-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 10.8 | -2.70% | 49,951 |
| 24-05-27 | 11.1 | -5.13% | 33,987 |
| 24-05-24 | 11.7 | +3.08% | 30,922 |
| 24-05-23 | 11.35 | -0.44% | 26,983 |
| 24-05-22 | 11.4 | +8.06% | 108,045 |
Delayed Quote Nasdaq Stockholm, May 28, 2024 at 11:23 am EDT
More quotes
Iconovo AB is a Sweden-based company, which offers inhalation solutions for pharmaceutical companies. Solutions are based on the Companyâs device platforms and include formulation, analytical testing and documentation. Iconovo Ab develops products, which are a part of device family and include: ICOres, reservoir devices, ICOone, disposable unit-dose devices, ICOcap, capsule-based devices and ICOpre, pre-metered devices. Moreover, the Company offers programs, which include development of generic inhalation products, where the products are registered based on therapeutic equivalence; development of inhalation products based on a generic application programming interface (API) and new chemical entity (NCE); as well as phase I-II clinical trials using ICOone.
Calendar
2024-07-11
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.49% | 16.65M | |
| +9.12% | 28.11B | |
| -36.79% | 3.03B | |
| -21.21% | 2.39B | |
| +5.74% | 2.18B | |
| -11.31% | 1.9B | |
| +21.11% | 1.88B | |
| +23.77% | 1.3B | |
| -14.16% | 1.23B | |
| -5.78% | 1.23B |
- Stock Market
- Equities
- ICO Stock
